Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was develo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Heo, Sook-Kyoung, Noh, Eui-Kyu, Yu, Ho-Min, Kim, Do Kyoung, Seo, Hye Jin, Lee, Yoo Jin, Cheon, Jaekyung, Koh, Su Jin, Min, Young Joo, Choi, Yunsuk, Jo, Jae-Cheol
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718665/
https://ncbi.nlm.nih.gov/pubmed/33276759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07701-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados